244 related articles for article (PubMed ID: 27174915)
1. IDO1 involvement in mTOR pathway: a molecular mechanism of resistance to mTOR targeting in medulloblastoma.
Folgiero V; Miele E; Carai A; Ferretti E; Alfano V; Po A; Bertaina V; Goffredo BM; Benedetti MC; Camassei FD; Cacchione A; Locatelli F; Mastronuzzi A
Oncotarget; 2016 Aug; 7(33):52900-52911. PubMed ID: 27174915
[TBL] [Abstract][Full Text] [Related]
2. Targeting mTOR as a Therapeutic Approach in Medulloblastoma.
Aldaregia J; Odriozola A; Matheu A; Garcia I
Int J Mol Sci; 2018 Jun; 19(7):. PubMed ID: 29932116
[TBL] [Abstract][Full Text] [Related]
3. Regulatory effects of a Mnk2-eIF4E feedback loop during mTORC1 targeting of human medulloblastoma cells.
Eckerdt F; Beauchamp E; Bell J; Iqbal A; Su B; Fukunaga R; Lulla RR; Goldman S; Platanias LC
Oncotarget; 2014 Sep; 5(18):8442-51. PubMed ID: 25193863
[TBL] [Abstract][Full Text] [Related]
4. Indoleamine 2,3-dioxygenase 1 (IDO1) is up-regulated in thyroid carcinoma and drives the development of an immunosuppressant tumor microenvironment.
Moretti S; Menicali E; Voce P; Morelli S; Cantarelli S; Sponziello M; Colella R; Fallarino F; Orabona C; Alunno A; de Biase D; Bini V; Mameli MG; Filetti S; Gerli R; Macchiarulo A; Melillo RM; Tallini G; Santoro M; Puccetti P; Avenia N; Puxeddu E
J Clin Endocrinol Metab; 2014 May; 99(5):E832-40. PubMed ID: 24517146
[TBL] [Abstract][Full Text] [Related]
5. mTOR pathway as a potential target in a subset of human medulloblastoma.
Pócza T; Sebestyén A; Turányi E; Krenács T; Márk A; Sticz TB; Jakab Z; Hauser P
Pathol Oncol Res; 2014 Oct; 20(4):893-900. PubMed ID: 24737380
[TBL] [Abstract][Full Text] [Related]
6. GD2 redirected CAR T and activated NK-cell-mediated secretion of IFNγ overcomes MYCN-dependent IDO1 inhibition, contributing to neuroblastoma cell immune escape.
Caforio M; Sorino C; Caruana I; Weber G; Camera A; Cifaldi L; De Angelis B; Del Bufalo F; Vitale A; Goffredo BM; De Vito R; Fruci D; Quintarelli C; Fanciulli M; Locatelli F; Folgiero V
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33737337
[TBL] [Abstract][Full Text] [Related]
7. Signaling pathway and molecular subgroups of medulloblastoma.
Li KK; Lau KM; Ng HK
Int J Clin Exp Pathol; 2013; 6(7):1211-22. PubMed ID: 23826403
[TBL] [Abstract][Full Text] [Related]
8. IDO1: An important immunotherapy target in cancer treatment.
Li F; Zhang R; Li S; Liu J
Int Immunopharmacol; 2017 Jun; 47():70-77. PubMed ID: 28365507
[TBL] [Abstract][Full Text] [Related]
9. A Novel Combination Approach Targeting an Enhanced Protein Synthesis Pathway in MYC-driven (Group 3) Medulloblastoma.
Chaturvedi NK; Kling MJ; Griggs CN; Kesherwani V; Shukla M; McIntyre EM; Ray S; Liu Y; McGuire TR; Sharp JG; Band H; Joshi SS; Coulter DW
Mol Cancer Ther; 2020 Jun; 19(6):1351-1362. PubMed ID: 32371591
[TBL] [Abstract][Full Text] [Related]
10. MiR-592 activates the mTOR kinase, ERK1/ERK2 kinase signaling and imparts neuronal differentiation signature characteristic of Group 4 medulloblastoma.
Paul R; Bapat P; Deogharkar A; Kazi S; Singh SKV; Gupta T; Jalali R; Sridhar E; Moiyadi A; Shetty P; Shirsat NV
Hum Mol Genet; 2021 Nov; 30(24):2416-2428. PubMed ID: 34274968
[TBL] [Abstract][Full Text] [Related]
11. PI-3K Inhibitors Preferentially Target CD15+ Cancer Stem Cell Population in SHH Driven Medulloblastoma.
Singh AR; Joshi S; Zulcic M; Alcaraz M; Garlich JR; Morales GA; Cho YJ; Bao L; Levy ML; Newbury R; Malicki D; Messer K; Crawford J; Durden DL
PLoS One; 2016; 11(3):e0150836. PubMed ID: 26938241
[TBL] [Abstract][Full Text] [Related]
12. Targeting cyclin-dependent kinase 9 sensitizes medulloblastoma cells to chemotherapy.
Song H; Bhakat R; Kling MJ; Coulter DW; Chaturvedi NK; Ray S; Joshi SS
Biochem Biophys Res Commun; 2019 Dec; 520(2):250-256. PubMed ID: 31594641
[TBL] [Abstract][Full Text] [Related]
13. PTEN-deficient prostate cancer is associated with an immunosuppressive tumor microenvironment mediated by increased expression of IDO1 and infiltrating FoxP3+ T regulatory cells.
Vidotto T; Saggioro FP; Jamaspishvili T; Chesca DL; Picanço de Albuquerque CG; Reis RB; Graham CH; Berman DM; Siemens DR; Squire JA; Koti M
Prostate; 2019 Jun; 79(9):969-979. PubMed ID: 30999388
[TBL] [Abstract][Full Text] [Related]
14. Galectin 3 protects from cisplatin-induced acute kidney injury by promoting TLR-2-dependent activation of IDO1/Kynurenine pathway in renal DCs.
Volarevic V; Markovic BS; Jankovic MG; Djokovic B; Jovicic N; Harrell CR; Fellabaum C; Djonov V; Arsenijevic N; Lukic ML
Theranostics; 2019; 9(20):5976-6001. PubMed ID: 31534532
[TBL] [Abstract][Full Text] [Related]
15. Signal Transducer and Activator of Transcription 1 Plays a Pivotal Role in RET/PTC3 Oncogene-induced Expression of Indoleamine 2,3-Dioxygenase 1.
Moretti S; Menicali E; Nucci N; Voce P; Colella R; Melillo RM; Liotti F; Morelli S; Fallarino F; Macchiarulo A; Santoro M; Avenia N; Puxeddu E
J Biol Chem; 2017 Feb; 292(5):1785-1797. PubMed ID: 27994058
[TBL] [Abstract][Full Text] [Related]
16. Marinopyrrole derivative MP1 as a novel anti-cancer agent in group 3 MYC-amplified Medulloblastoma.
Coulter DW; Chhonker YS; Kumar D; Kesherwani V; Aldhafiri WN; McIntyre EM; Alexander G; Ray S; Joshi SS; Li R; Murry DJ; Chaturvedi NK
J Exp Clin Cancer Res; 2024 Jan; 43(1):18. PubMed ID: 38200580
[TBL] [Abstract][Full Text] [Related]
17. Overexpression of HMGA1 deregulates tumor growth via cdc25A and alters migration/invasion through a cdc25A-independent pathway in medulloblastoma.
Lau KM; Chan QK; Pang JC; Ma FM; Li KK; Yeung WW; Cheng AS; Feng H; Chung NY; Li HM; Zhou L; Wang Y; Mao Y; Ng HK
Acta Neuropathol; 2012 Apr; 123(4):553-71. PubMed ID: 22249617
[TBL] [Abstract][Full Text] [Related]
18. Deficiency in the Treatment Description of mTOR Inhibitor Resistance in Medulloblastoma, a Systematic Review.
Alammar H; Nassani R; Alshehri MM; Aljohani AA; Alrfaei BM
Int J Mol Sci; 2021 Dec; 23(1):. PubMed ID: 35008889
[TBL] [Abstract][Full Text] [Related]
19. BMI1 is a therapeutic target in recurrent medulloblastoma.
Bakhshinyan D; Venugopal C; Adile AA; Garg N; Manoranjan B; Hallett R; Wang X; Mahendram S; Vora P; Vijayakumar T; Subapanditha M; Singh M; Kameda-Smith MM; Qazi M; McFarlane N; Mann A; Ajani OA; Yarascavitch B; Ramaswamy V; Farooq H; Morrissy S; Cao L; Sydorenko N; Baiazitov R; Du W; Sheedy J; Weetall M; Moon YC; Lee CS; Kwiecien JM; Delaney KH; Doble B; Cho YJ; Mitra S; Kaplan D; Taylor MD; Davis TW; Singh SK
Oncogene; 2019 Mar; 38(10):1702-1716. PubMed ID: 30348991
[TBL] [Abstract][Full Text] [Related]
20. Developmental phosphoproteomics identifies the kinase CK2 as a driver of Hedgehog signaling and a therapeutic target in medulloblastoma.
Purzner T; Purzner J; Buckstaff T; Cozza G; Gholamin S; Rusert JM; Hartl TA; Sanders J; Conley N; Ge X; Langan M; Ramaswamy V; Ellis L; Litzenburger U; Bolin S; Theruvath J; Nitta R; Qi L; Li XN; Li G; Taylor MD; Wechsler-Reya RJ; Pinna LA; Cho YJ; Fuller MT; Elias JE; Scott MP
Sci Signal; 2018 Sep; 11(547):. PubMed ID: 30206138
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]